Publications & Works

Publication Network
Articles 30
All (30)
SCI-E, SSCI, AHCI (20)
SCI-E, SSCI, AHCI, ESCI (28)
ESCI (8)
Scopus (28)
TRDizin (5)
Other Publications (1)

1. Promising Antimycobacterial Agents: Salicylidenehydrazines

ÜNSAL TAN O., Vagolu S. K., Tonjum T., KAPLAN O., ŞİMŞEK R.
ARCHIV DER PHARMAZIE , vol.358, no.7, 2025 (SCI-Expanded) Sustainable Development identifier identifier

2. Metabolomic Profiling Reveals Distinct Pathways in Degenerated and Non-degenerated Rotator Cuff Tears: Implications for Pathogenesis and Treatment

Bulbul F., Koc E., Fidan B. B., KAPLAN O., Ruzgar H., BİLGE O., et al.
CURRENT MOLECULAR MEDICINE , 2025 (SCI-Expanded) identifier identifier

3. Donor tissue type alters the effects of mesenchymal stem cells on human osteoarthritic chondrocytes and their metabolomic profiles

KARAÇOBAN L., Gizer M., Fidan B. B., KAPLAN O., ÇELEBİER M., Korkusuz P., et al.
RESEARCH IN SPORTS MEDICINE , 2025 (SCI-Expanded) identifier identifier

4. Altered plasma levels of arachidonic acid, choline, amino acids, and sphingolipids signal neural tube defects Altered plasma metabolite profiles associated with neural tube defects

Ozel S., KAPLAN O., Fidan B. B., ÇELEBİER M., Engin-Ustun Y.
AIMS MOLECULAR SCIENCE , no.1, pp.99-112, 2025 (ESCI) identifier

5. Metabolomic signature in ocular dosing: Exploring the metabolic impacts of sublethal high-dose naringenin on ARPE-19 cells

KAPLAN O., Koc E., TÜRK S., Kucukkilinc T. T., GÖKTAŞ Z., ÇELEBİER M.
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE , vol.72, 2024 (SCI-Expanded) identifier identifier

6. A Facile and Efficient Protocol for Phospholipid Enrichment in Synovial Joint Fluid: Monodisperse-Mesoporous SiO2 Microspheres as a New Metal Oxide Affinity Sorbent

Aladag S., Demirdis I., GÖKÇAL KAPUCU B., Koc E., KAPLAN O., AKTAŞ B. E., et al.
SEPARATIONS , vol.11, no.9, 2024 (SCI-Expanded) identifier identifier

7. A Comprehensive Examination of UV-VIS Spectrophotometric Methods in Pharmaceutical Analysis Between 2015-2023

Enes D., Dastan K., KAPLAN O., ÇELEBİER M., DOĞAN A.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING , no.7, pp.1125-1132, 2024 (SCI-Expanded) Sustainable Development identifier identifier

8. An Isolated Perfused Rat Liver Model: Simultaneous LC-MS Quantification of Pitavastatin, Coproporphyrin I, and Coproporphyrin III Levels in the Rat Liver and Bile

İZAT N., KAPLAN O., ÇELEBİER M., ŞAHİN S.
ACS OMEGA , vol.9, no.17, pp.19250-19260, 2024 (SCI-Expanded) Sustainable Development identifier identifier identifier

9. Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles

Topcu B. T., KAPLAN O., Pehlivan S. B., ÇELEBİER M., ÖNER L.
JOURNAL OF CHEMICAL METROLOGY , vol.18, pp.10-18, 2024 (ESCI) Creative Commons License identifier identifier

10. Plasma metabolomics for diagnostic biomarkers on ectopic pregnancy

KAPLAN O., Ertürk Aksakal S., Fidan B. B., Engin-Üstün Y., ÇELEBİER M.
Scandinavian Journal of Clinical and Laboratory Investigation , vol.84, no.1, pp.44-52, 2024 (SCI-Expanded) identifier identifier identifier

11. RP-HPLC method combined with ultrafiltration for simultaneous analysis of Melphalan and Topotecan in human plasma samples

KAPLAN O., Yilmaz N., UÇAR B., ALGEDİK TOKYÜREK M. Ö., KOÇ İ., KIRATLI H., et al.
JOURNAL OF CHEMICAL METROLOGY , vol.18, pp.30-40, 2024 (ESCI) Creative Commons License Sustainable Development identifier identifier

12. Development and UV-VIS Spectrophotometric analysis of an ease-of-use pediatric oral solution of dexamethasone for personalized therapies

Enes D., Fidan B. B., KAPLAN O., DOĞAN A., Altinoz S., ÇELEBİER M., et al.
JOURNAL OF RESEARCH IN PHARMACY , vol.28, no.5, pp.1791-1799, 2024 (ESCI, Scopus, TRDizin) identifier identifier identifier

13. Effects of genetic polymorphisms of CYP2J2, CYP2C9, CYP2C19, CYP4F2, CYP4F3 and CYP4A11 enzymes in preeclampsia and gestational hypertension

Ongun M. C., Tonyali N. V., KAPLAN O., DEĞER İ., ÇELEBİER M., BAŞCI AKDUMAN N. E., et al.
Placenta , vol.137, pp.88-95, 2023 (SCI-Expanded) identifier identifier identifier

14. A Plant Metabolomic Approach to Identify the Difference of the Seeds and Flowers Extracts of Carthamus tinctorius L.

KAPLAN O., SALTAN N., Köse A., KÖSE Y. B., ÇELEBİER M.
Mass Spectrometry Letters , vol.14, no.2, pp.42-47, 2023 (ESCI) identifier identifier

15. Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on HepG2 cancer cell lines

Şenol Y., KAPLAN O., VARAN C., Demirtürk N., Öncül S., Fidan B. B., et al.
Journal of Drug Delivery Science and Technology , vol.79, 2023 (SCI-Expanded) Sustainable Development identifier identifier

16. Plasma irisin and metabolomic response differ between concentric and isometric exercise Effets différents de l'exercice concentrique et de l'exercice isométrique sur l'irisine plasmatique et la réponse métabolomique

KARA Ö. S., ERCAN A., ÇELEBİER M., KAPLAN O., ÖNCÜL S., KORKUSUZ F.
Science and Sports , vol.37, no.7, pp.610-617, 2022 (SCI-Expanded) identifier identifier

17. A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients

Solmaz İ., KAPLAN O., ÇELEBİER M., LAY İ., Anlar B.
Turkish Journal of Medical Sciences , vol.52, no.4, pp.1299-1310, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier identifier

18. Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells

Varol I., KAPLAN O., Erdoğar N., Öncül S., Nielsen T. T., ERCAN A., et al.
Current Pharmaceutical Analysis , vol.17, no.10, pp.1272-1281, 2021 (SCI-Expanded) Sustainable Development identifier identifier

19. Comparison of Different Sample Preparation Techniques for Untargeted Metabolomics Utilizing Q-TOF LC/MS and MetaboAnalyst 4.0

Kaplan O., Koçak E., Çelebier M.
Current Metabolomics and Systems Biology , vol.8, pp.53-60, 2021 (Peer-Reviewed Journal)

20. Bioanalytical Method Validation of an RP-HPLC Method for Determina-tion of Rifampicin in Liver Perfusion Studies

İZAT N., KAPLAN O., ÇELEBİER M., ŞAHİN S.
CURRENT PHARMACEUTICAL ANALYSIS , vol.17, no.7, pp.919-925, 2021 (SCI-Expanded) identifier identifier

21. UPLC-Q-TOF/MS based Untargeted Metabolite and Lipid Analysis on Premature Ovarian Insufficiency Plasma Samples

Tasci Y., Findik R. B., Pekcan M. K., KAPLAN O., ÇELEBİER M.
CURRENT PHARMACEUTICAL ANALYSIS , vol.17, no.4, pp.474-483, 2021 (SCI-Expanded) identifier identifier

22. Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis

DEMİR S., KAPLAN O., ÇELEBİER M., SAĞ E., BİLGİNER Y., LAY İ., et al.
Seminars in Arthritis and Rheumatism , vol.50, no.6, pp.1238-1244, 2020 (SCI-Expanded) Sustainable Development identifier identifier identifier

23. Polycystic ovary syndrome in adolescents: Q-TOF LC/MS analysis of human plasma metabolome

ÇELEBİER M., KAPLAN O., Özel Ş., Engin-Üstün Y.
Journal of Pharmaceutical and Biomedical Analysis , vol.191, 2020 (SCI-Expanded) identifier identifier identifier

24. Evaluation of Recent Data Processing Strategies on Q-TOF LC/MS Based Untargeted Metabolomics

KAPLAN O., ÇELEBİER M.
MASS SPECTROMETRY LETTERS , vol.11, no.1, pp.1-5, 2020 (ESCI) identifier identifier

25. Past, present and future of metabolomic studies Metabolomik çalışmaların dünü, bugünü ve yarını

KAPLAN O., ÇELEBİER M.
Turkiye Klinikleri Journal of Medical Sciences , vol.40, no.3, pp.366-374, 2020 (SCI-Expanded) Sustainable Development identifier

26. Comparison of cell lysis techniques via q-tof lc/ms

KAPLAN O., ÖNCÜL S., ERCAN A., ÇELEBİER M.
Mass Spectrometry Letters , vol.11, no.2, pp.36-40, 2020 (ESCI) Sustainable Development identifier identifier

27. Liquid-liquid extraction and ultrafiltration based sample preparation technique for Q-TOF LC/MS analysis of non-polar metabolites in human plasma samples

KOÇAK E., KAPLAN O., ÇELEBİER M.
Journal of Research in Pharmacy , vol.24, no.1, pp.38-43, 2020 (ESCI) Creative Commons License identifier identifier

28. Discovery of Michael acceptor containing 1,4-dihydropyridines as first covalent inhibitors of L-/T-type calcium channels

Cevher H. A., Schaller D., Gandini M. A., KAPLAN O., Gambeta E., Zhang F. X., et al.
BIOORGANIC CHEMISTRY , vol.91, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

29. Determination of the physicochemical properties of piroxicam

ÇELEBİER M., NENNİ M., KAPLAN O., AKGEYİK E., KAYNAK M. S., ŞAHİN S.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES , vol.0, no.0, 2019 (Scopus) Creative Commons License identifier

30. Global omics strategies to investigate the effect of cyclodextrin nanoparticles on MCF-7 breast cancer cells

ERCAN A., ÇELEBİER M., VARAN G., ÖNCÜL S., Nenni M., KAPLAN O., et al.
European Journal of Pharmaceutical Sciences , vol.123, pp.377-386, 2018 (SCI-Expanded) Sustainable Development identifier identifier identifier
Papers Presented at Peer-Reviewed Scientific Conferences 10

1. Validation of an HPLC method for the determination of talazoparib from nanoparticle formulations

Taş B., Akdağ Çaylı Y., Aytekin E., Pehlivan S., Öner L., Kaplan O.
3rd International Gazi Pharma Symposium Series (GPSS-2021), 8 - 10 September 2021, pp.1-2, (Summary Text)

2. AN INNOVATIVE SAMPLE PREPARATION TECHNIQUE TO EVALUATE THE DIFFERENCES IN METABOLOME LEVELS FOR SYNOVIA AND FAT TISSUES

KARAÇOBAN L., KAPLAN O., MENDERES Y., ÇELEBİER M., KORKUSUZ F.
European Orthopaedic Research Society 28th Annual Meeting Congress, İzmir, Turkey, 17 - 18 September 2020, (Summary Text)

3. Bioanalytical Validation of an HPLC Method for the Analysis of Rifampicin Accumulation in Rat Liver

İzat N., Kir F., Kaplan O., Çelebier M., Şahin S.
8. BBBB International Conference on Pharmaceutical Sciences (8.BBBB 2019), İzmir, Turkey, 14 - 16 October 2019, pp.332-333, (Summary Text)

4. Comparison of different sample preparation techniques on human plasma samples for Q-TOF LC/MS based metabolite profiling

ÇELEBİER M., KAPLAN O., KOÇAK E.
Euroanalysis 2019, İstanbul, Turkey, 1 - 05 July 2019, (Full Text)

5. Comparison of Metabolite Extraction Techniques for LC/MS Based Metabolomics on Human Blood Plasma

KAPLAN O., KOÇAK E., ÇELEBİER M.
International Multisciplinary Symposium on Drug Research Development - DRD 2019, Malatya, Turkey, 1 - 03 July 2019, (Full Text)

6. Is It Possible To Use Pooled Plasma Samples For Large-Scale Human Metabolomic Studies? A Comparison Of The Metabolite Profiles Of Pooled Plasma Samples With Random Individual Samples Using Q-TOF LC/MS

ÇELEBİER M., KAPLAN O., OZEL Ş., ÜSTÜN Y., KOÇAK E.
1st International Congress on Analytical and Bioanalytical Chemistry, Antalya, Turkey, 27 - 30 March 2019, (Full Text)

7. Evaluation of Antimicrobial Effect of Simvastatin on E. coli with Metabolomics Analysis

KOÇAK E., ÖZKUL KOÇAK C., KAPLAN O., ÇELEBİER M., NEMUTLU E., KIR S., et al.
1st International Congress on Analytical and Bioanalytical Chemistry, Antalya, Turkey, 27 March 2019, (Full Text)

8. A Metabolomic Study to Investigate the Effect of Folate Conjugated Nanoparticles on Triple Negative Breast Cancer Cells

ERCAN A., ÇELEBİER M., varol ı., KAPLAN O., Varan G., ÖNCÜL S., et al.
EUFEPS Annual Meeting 2019 PERSONALIZED MEDICINES,TARGETED THERAPIES,PRECISION DRUG DELIVERY, 6 - 08 March 2019, (Full Text) Sustainable Development

9. The effect of polycationic amphiphilic cyclodestrin nanoparticles on mda-mb cancer cells: A metabolomic approach to understand the mechanism

ÇELEBİER M., KAPLAN O., VARAN G., ÖNCÜL S., KOÇAK E., ERCAN A., et al.
12 th International symposium on pharmaceutical sciences, 26 June 2018, (Summary Text) Sustainable Development

10. GENOMIC AND METABOLOMIC STUDIES OF POLYCATIONIC AMPHIPHILIC CYCLODEXTRIN NANOPARTICLESON HEPG2 CELL LINE

ERCAN A., ÇELEBİER M., Varan G., ÖNCÜL S., KOÇAK E., KAPLAN O., et al.
EUFEPS Annual Meeting 2018 Crossing Barriers for Future Medicines, 24 - 26 May 2018, (Full Text)
Metrics

Publication

40

Publication (WoS)

28

Publication (Scopus)

28

Citation (WoS)

51

H-Index (WoS)

5

Citation (Scopus)

52

H-Index (Scopus)

5

Citation (Scholar)

69

H-Index (Scholar)

1

Project

9

Open Access

5
UN Sustainable Development Goals